Results 51 to 60 of about 36,256 (261)

Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives [PDF]

, 2016
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases.
ARPINO, GRAZIA, DE PLACIDO, SABINO, GIULIANO, MARIO, SCHETTINI, FRANCESCO   +3 more
core   +1 more source

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches.
Keiichi Akahoshi, Shun Kaneko, Shinji Tanaka, Minoru Tanabe, Daisuke Ban   +4 more
wiley   +1 more source

Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma

Therapeutic Advances in Medical Oncology
Background: The HIMALAYA trial found that durvalumab plus tremelimumab significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma (HCC) compared with sorafenib.
Weiting Liao, Huiqiong Xu, David Hutton, Qiuji Wu, Yang Yang, Mingyang Feng, Wanting Lei, Liangliang Bai, Junying Li, Qiu Li   +9 more
doaj   +1 more source

Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Radiation Oncology, 2023
Background The current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined with durvalumab consolidation therapy.
Mai Sakagami, Haruo Inokuchi, Nobutaka Mukumoto, Hiroshige Itoyama, Nobunari Hamaura, Mutsumi Yamagishi, Naoki Mukumoto, Shogo Matsuda, Daijiro Kabata, Keiko Shibuya   +9 more
doaj   +1 more source

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. [PDF]

, 2019
BACKGROUND:Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is ...
Baste, Neus, Clayburgh, Daniel, Cohen, Ezra EW, Fountzilas, George, Fujii, Takashi, Khaliq, Asud, Kim, Edward S, Lin, Derrick, Lipworth, Loren, Mehlhorn, Holger, Melillo, Giovanni, Pai, Sara I, Resteghini, Carlo, Shara, Nawar, Shire, Norah, Stokes, Michael, Twumasi-Ankrah, Philip, Wang, Huifen, Wildsmith, Sophie, Zhang, Jun   +19 more
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

Thoracic Cancer, 2020
Background Chemoradiotherapy followed by durvalumab is the standard treatment for the patients with local advanced non‐small cell lung cancer (NSCLC). There is a real‐world data about the management of adverse events, such as pneumonitis, according to ...
Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu   +14 more
doaj   +1 more source

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Frontiers in Oncology, 2021
IntroductionFor unresectable stage III non-small cell lung cancer (NSCLC), the standard therapy consists of chemoradiotherapy (CRT) followed by durvalumab maintenance for responding patients.
Alessio Bruni, Vieri Scotti, Paolo Borghetti, Stefano Vagge, Salvatore Cozzi, Elisa D’Angelo, Niccolò Giaj Levra, Alessandra Fozza, Maria Taraborrelli, Gaia Piperno, Valentina Vanoni, Matteo Sepulcri, Marco Trovò, Valerio Nardone, Elisabetta Lattanzi, Said Bou Selman, Federica Bertolini, Davide Franceschini, Francesco Agustoni, Barbara Alicja Jereczek-Fossa, Barbara Alicja Jereczek-Fossa, Stefano Maria Magrini, Lorenzo Livi, Frank Lohr, Andrea Riccardo Filippi   +24 more
doaj   +1 more source

The importance for immunoregulation for long-term cancer control. [PDF]

, 2017
Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma, the combination of ipilimumab with nivolumab showed high efficacy.
Alberto Fusi, Angus Dalgleish, Chan TA, Chen RW, Fryer RA, Hyunjoon K, Weber J   +6 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source